Many think that the beginning of 2016 is going to be filled with slow equities. However, it turns out that there are a few sectors that may make investments worthwhile. One of the biggest industries being looked into is the biotechnology industry. There are several factors contributing to the belief that 2016 will be a good year for the biotech industry. The first quarter specifically will likely hint at the long term profitability. If the news is positive, as most investors are expecting for it to be, then a good amount of stocks in the industry will see rises come at the front end of the year, which is why certain biotech stocks are a must own in a very weak market.
More specifically, companies working with vaccines can expect to see nice returns this year. Companies such as this typically have seen major funds for research and development efforts. In addition, new technologies are also being given to lessen the time taken for development and discovery. Even though vaccines are successful, there are still more than forty huge diseases that require vaccinations. Over 120 vaccines are set to enter the market within the next give years. As a result, the Global vaccine market is poised to grow by a CAGR of around 12.4 % all the way to 2020.
VBIV’s other platform is a “thermostable technology” that allows for the development of vaccines and biologics that can save vaccine strength and maintain storage or shipment at different temperatures. VBI Vaccines Inc (NASDAQ:VBIV) has finished proof of concept thermostability research on sundry vaccine and biologic targets. VBIV is headquartered in Cambridge, MA with research facilities in Ottawa, Canada. On Monday, the company announced that it would be presenting at the Noble Financial Emerging Growth Investor Conference. Because of VBIV’s efforts in a growing industry, it would not be a bad idea to look into it to start the new year.